NCT07710846

Brief Summary

The purpose of this Patient Identification and Characterization (PIC) study is to collect information and perform limited allergy-related procedures to determine if participants can qualify for cat and/or birch tree pollen allergy clinical research studies in the future. The study is also looking at how cat and/or birch tree pollen allergies have affected overall health.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,500

participants targeted

Target at P75+ for all trials

Timeline
17mo left

Started Aug 2026

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 13, 2026

Completed
4 days until next milestone

First Posted

Study publicly available on registry

July 17, 2026

Completed
1 month until next milestone

Study Start

First participant enrolled

August 17, 2026

Expected
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 10, 2028

Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 10, 2028

Last Updated

July 17, 2026

Status Verified

July 1, 2026

Enrollment Period

1.4 years

First QC Date

July 13, 2026

Last Update Submit

July 13, 2026

Conditions

Conjunctivitis Allergic

Keywords

Cat and/or birch allergen induced allergic conjunctivitisCat allergyBirch pollen allergyEye allergyCat-induced eye allergyOcular allergy signs/symptomsAllergic conjunctivitis signs/symptoms

Outcome Measures

Primary Outcomes (2)

  • Proportion of participants with moderate-to-severe allergic conjunctivitis due to cat allergy who report "very bothered" or "extremely bothered" by allergic symptoms upon exposure to cat and/or cat hair/dander

    Part A

    At visit 1, up to 30 days

  • Proportion of participants with moderate-to-severe allergic conjunctivitis due to birch tree pollen allergy who report "very bothered" or "extremely bothered" by allergic symptoms

    Part B

    At visit 1, up to 30 days

Secondary Outcomes (2)

  • Proportion of participants who report "very bothered" or "extremely bothered" by allergic symptoms upon exposure to cat and/or cat hair/dander

    At visit 1, up to 30 days

  • Proportions of participants who report "very bothered" or "extremely bothered" by allergic symptoms due to birch tree pollen

    At visit 1, up to 30 days

Study Arms (2)

Part A

Cat allergy

Other: Noninterventional

Part B

Birch allergy

Other: Noninterventional

Interventions

NoninterventionalOTHER

No investigational medicinal products will be administered in this study.

Part APart B

Eligibility Criteria

Age5 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

This study will enroll adult and pediatric (aged ≥5 to \<18 years) participants with cat and/or birch allergen induced allergic conjunctivitis with or without allergic rhinitis

You may qualify if:

  • Adults or pediatric participants, ≥5 years of age inclusive (pediatric participants ≥5 years and \<18 years and weighing ≥10 kg, to be enrolled where permitted per local regulations/approvals), at the time of signing the informed consent
  • Participant-reported (and/or caregiver-reported for pediatric participants) and/or documented allergic history as described in the protocol
  • Positive Skin Prick Test (SPT) at screening: to cat allergen (Part A) and/or to birch allergen (Part B)
  • Must not currently live with a cat(s) or have lived with a cat(s) in the home for the past 1 year (Part A)
  • Willing and able to comply with clinic visit(s) and study-related assessments

You may not qualify if:

  • Presence of any ophthalmic disease/abnormality/condition that may interfere with study assessments, affect the study outcomes or participant safety as described in the protocol
  • History of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnia, respiratory arrest, and/or hypoxic seizures
  • Active, chronic infections requiring long-term use of systemic antibiotics, antivirals, or anti-fungal treatments

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Biospecimen

Retention: SAMPLES WITH DNA

blood, urine or serum

MeSH Terms

Conditions

Conjunctivitis, Allergic

Condition Hierarchy (Ancestors)

ConjunctivitisConjunctival DiseasesEye DiseasesHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Study Officials

  • Clinical Trial Management

    Regeneron Pharmaceuticals

    STUDY DIRECTOR

Central Study Contacts

Clinical Trials Administrator

CONTACT

844-734-6643clinicaltrials@regeneron.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 13, 2026

First Posted

July 17, 2026

Study Start (Estimated)

August 17, 2026

Primary Completion (Estimated)

January 10, 2028

Study Completion (Estimated)

January 10, 2028

Last Updated

July 17, 2026

Record last verified: 2026-07

Data Sharing

IPD Sharing
Will not share